PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q87150

Hideki FUJIKURA, et al.

Appln. No.: 10/529,895 Group Art Unit: 1614

Confirmation No.: 6607 Examiner: NOT YET ASSIGNED

Filed: September 19, 2005

For: PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME,

MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction:

Assignment for Published Patent Application

KISSEI PHARMACEUTICAL CO., LTD.

Verification for the requested correction is indicated on the enclosed copy of the original Assignment filed September 19, 2005.

Respectfully submitted,

Peter D. Olexy

Registration No. 24,513

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 26, 2006



23373

SUITE 800

SUGHRUE MION, PLLC

WASHINGTON, DC 20037

2100 PENNSYLVANIA AVENUE, N.W.

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO BOX 1450 Alexandra, Vingana 22813-1450 www.inspin.gov

FILING OR 371 ART UNIT FIL FEE REC'D APPL NO. ATTY.DOCKET NO **DRAWINGS** TOT CLMS IND CLMS (c) DATE 10/529,895 09/19/2005 1614 1380 Q87150 23 4

CONFIRMATION NO. 6607

FILING RECEIPT

OC000000017891333

Date Mailed: 01/23/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Hideki Fujikura, Nagano, JAPAN: Norihiko Kikuchi, Nagano, JAPAN: Shigeki Tazawa, Nagono, JAPAN; Tokuhisa Yamato, Nagano, JAPAN; Masayuki Isaji, Nagano, JAPAN:

Assamuat UL Publi Sluid icient MISSEL PHARLIACELITICAL

Power of Attorney: The patent practitioners associated with Customer Number 23373.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/12477 09/30/2003

Foreign Applications

JAPAN 2002293090 10/04/2002 JAPAN 2002330694 11/14/2002 JAPAN 2002378959 12/27/2002

Projected Publication Date: 05/04/2006

Non-Publication Request: No

Early Publication Request: No

Assignment

have i COM INTE	Whereas, I/We, Hideki FUJIKURA, Norihiko KIKUCHI, Shigeki TAZAWA, Tokuhisa ATO, Masayuki ISAJI of all of Nagano, Japan,, respectively, hereinafter called assignor(s), invented certain improvements in PYRAZOLE DERIVATIVE, MEDICINAL POSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND RMEDIATE IN PRODUCING THE SAME and executed an application for Letters Patent United States of America therefor on; and
_	Whereas, KISSEI PHARMACEUTICAL CO., LTD., 19-48, Yoshino, Matsumoto-shi, no 399-8710 Japan (assignee), desires to acquire the entire right, title, and interest in the eation and invention, and to any United States patents to be obtained therefor;
	Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,
inventunder issue a succes neces	I/We, the above named assignor(s), hereby sell, assign and transfer to the above named nee, its successors and assigns, the entire right, title and interest in the application and the tion disclosed therein for the United States of America, including the right to claim priority 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to any Letters Patent granted upon the invention set forth in the application to the assignee, its ssors and assigns; and I/we will execute without further consideration all papers deemed sary by the assignee in connection with the United States application when called upon to by the assignee.
(Appl	I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 sylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses lication number and Confirmation number, filed) oplication number and filing date of said application when known.
Date:	April 4, 2005 S/Hideki FUJIKURA
Date:	March 3/ 2005 Norihiko Kikuchi. s/Norihiko KIKUCHI
Date:	March 31, 2005 Shigeki Tazawa s/Shigeki TAZAWA
Date:	March 30, 2005 Johnhisa Yamato s/Tokuhisa YAMATO
Date:	March 31, 2==5 Masayaki Isaji s/Masayuki ISAJI

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)